Cancer Research Annual Meeting 2010 Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beauregard, D. A.
Right arrow Articles by Brindle, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beauregard, D. A.
Right arrow Articles by Brindle, K. M.
[Cancer Research 61, 6811-6815, September 15, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

The Susceptibility of Tumors to the Antivascular Drug Combretastatin A4 Phosphate Correlates with Vascular Permeability1

Daniel A. Beauregard, Sally A. Hill, Dai J. Chaplin and Kevin M. Brindle2

Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA [D. A. B., K. M. B.], and Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR [S. A. H., D. J. C.], United Kingdom

The acute effects of the antivascular drug, combretastatin A4 phosphate, on tumor energy status and perfusion were assessed using magnetic resonance imaging (MRI) and spectroscopy. Localized 31P magnetic resonance spectroscopy showed that LoVo and RIF-1 tumors responded well to drug treatment, with significant increases in the Pi/nucleoside triphosphate ratio within 3 h, whereas SaS, SaF, and HT29 tumors did not respond to the same extent. This variable response was also seen in MRI experiments in which tumor perfusion was assessed by monitoring the kinetics of inflow of the contrast agent, gadolinium diethylenetriaminepentaacetate. These data were analyzed to give the initial rate and time constant for inflow of contrast agent and the integral under the inflow curve. The differential susceptibility of the tumors to combretastatin A4 phosphate showed a positive correlation with prior MRI measurements of tumor vascular permeability, which was determined by measuring the inflow of a macromolecular contrast agent, BSA-gadolinium diethylenetriaminepentaacetate.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
G. M. Tozer, V. E. Prise, G. Lewis, S. Xie, I. Wilson, and S. A. Hill
Nitric Oxide Synthase Inhibition Enhances the Tumor Vascular-Damaging Effects of Combretastatin A-4 3-O-Phosphate at Clinically Relevant Doses
Clin. Cancer Res., June 1, 2009; 15(11): 3781 - 3790.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
G M Tozer, C Kanthou, G Lewis, V E Prise, B Vojnovic, and S A Hill
Tumour vascular disrupting agents: combating treatment resistance
Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S12 - S20.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Strieth, M. E. Eichhorn, A. Werner, B. Sauer, M. Teifel, U. Michaelis, A. Berghaus, and M. Dellian
Paclitaxel Encapsulated in Cationic Liposomes Increases Tumor Microvessel Leakiness and Improves Therapeutic Efficacy in Combination with Cisplatin
Clin. Cancer Res., July 15, 2008; 14(14): 4603 - 4611.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. M. Tozer, S. Akerman, N. A. Cross, P. R. Barber, M. A. Bjorndahl, O. Greco, S. Harris, S. A. Hill, D. J. Honess, C. R. Ireson, et al.
Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors
Cancer Res., April 1, 2008; 68(7): 2301 - 2311.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Hyodo, K.-i. Matsumoto, A. Matsumoto, J. B. Mitchell, and M. C. Krishna
Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents.
Cancer Res., October 15, 2006; 66(20): 9921 - 9928.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
F. Chen, X. Sun, F. De Keyzer, J. Yu, R. Peeters, W. Coudyzer, V. Vandecaveye, W. Landuyt, H. Bosmans, P. Van Hecke, et al.
Liver Tumor Model with Implanted Rhabdomyosarcoma in Rats: MR Imaging, Microangiography, and Histopathologic Analysis
Radiology, May 1, 2006; 239(2): 554 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. V. Skliarenko, S. J. Lunt, M. L. Gordon, A. Vitkin, M. Milosevic, and R. P. Hill
Effects of the Vascular Disrupting Agent ZD6126 on Interstitial Fluid Pressure and Cell Survival in Tumors
Cancer Res., February 15, 2006; 66(4): 2074 - 2080.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Seshadri, J. A. Spernyak, R. Mazurchuk, S. H. Camacho, A. R. Oseroff, R. T. Cheney, and D. A. Bellnier
Tumor Vascular Response to Photodynamic Therapy and the Antivascular Agent 5,6-Dimethylxanthenone-4-Acetic Acid: Implications for Combination Therapy
Clin. Cancer Res., June 1, 2005; 11(11): 4241 - 4250.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
H. C. Thoeny, F. De Keyzer, F. Chen, Y. Ni, W. Landuyt, E. K. Verbeken, H. Bosmans, G. Marchal, and R. Hermans
Diffusion-weighted MR Imaging in Monitoring the Effect of a Vascular Targeting Agent on Rhabdomyosarcoma in Rats
Radiology, March 1, 2005; 234(3): 756 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Evelhoch, P. M. LoRusso, Z. He, Z. DelProposto, L. Polin, T. H. Corbett, P. Langmuir, C. Wheeler, A. Stone, J. Leadbetter, et al.
Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126
Clin. Cancer Res., June 1, 2004; 10(11): 3650 - 3657.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. E. Thorpe
Vascular Targeting Agents as Cancer Therapeutics
Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
K M Brindle
Molecular imaging using magnetic resonance: new tools for the development of tumour therapy
Br. J. Radiol., December 1, 2003; 76(suppl_2): S111 - S117.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. Nambu, R. Nambu, M. Melia, and P. A. Campochiaro
Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3650 - 3655.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. Anderson, J. T. Yap, M. P. Miller, A. Robbins, T. Jones, and P. M. Price
Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate
J. Clin. Oncol., August 1, 2003; 21(15): 2823 - 2830.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Galbraith, R. J. Maxwell, M. A. Lodge, G. M. Tozer, J. Wilson, N. J. Taylor, J. J. Stirling, L. Sena, A. R. Padhani, and G. J.S. Rustin
Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging
J. Clin. Oncol., August 1, 2003; 21(15): 2831 - 2842.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.